It is now well known that treatment of tumors, especially non-small-cell lung cancer (NSCLC), remains limited and it is urgent to develop strategies that target tumor cells and their genetic features. In this regard, our work is about genetic modifications arising in an in vitro NSCLC cell line after treatment with a chemical substance, methyl 4-methoxy-3-(3-methyl-2-butenoyl) benzoate (VT1). First, we showed that VT1 induces arrest of proliferation by blocking cells in the G1 phase of the cell cycle. Second, we use "differential display" strategy to clarify the genetic mechanisms involved in this proliferation arrest. A novel mRNA, NY-CO-1 (New-York Colon 1), of unknown function showed up-regulated expression after treatment. The use of chemotherapeutic agents in the treatment of tumors is limited by several factors including innate or acquired drug resistance and systemic toxicity. 1 In bronchopulmonary carcinomas, chemotherapy remains relatively inactive against these cancers, with a poor response rate and a survival benefit limited to a period of a few weeks or months. 2,3 Accordingly, new treatment approaches need to be considered.In this context, the first purpose of our study was to investigate the biological activity of a chemical constituent, methyl 4-methoxy-3-(3-methyl-2-butenoyl) benzoate, also named VT1, in an NSCLC cell line derived from a human non-small-cell lung carcinoma. VT1 is a synthetic molecule obtained after chemical modifications of a precursor molecule of natural origin extracted from Piper-Toboganum. 4 The NSCLC cell line shows a chemosensitivity for conventional drugs close to clinical doses, making it an excellent model for studying the biological activity of new products, 5 including marine substances that have shown biological activity on this cell line. 6 -8 The present study, which investigated VT1 cellular and molecular mechanisms of action on the human NSCLC cell line, found that proliferation could be stopped by incubation with VT1. The cellular mechanisms involved induction of programmed cell death of apoptotic type, which was associated with cellular morphological modifications and cell cycle blockade in the G1 phase.Many studies have presented previously genetic factors involved in cell death. They include nuclear factors like p53 and its partners, p21 and GADD45, 9 but also cytoplasmic and extracellular factors like the bcl-2 gene family, 10 caspases 11 or FAS ligand and TNF␣. 12 In tumor cells these factors are often inactive (mutation in the p53 gene), but it is possible to engage these cells in a programmed cell death after treatment by a certain type of substance. The latter shows that other genetic factors implicated in programmed cell death should exist and, finally, that tumor cells are a good model for characterizing them.Thus, the second purpose of our study was to clarify the genetic mechanisms involved in proliferation arrest of the human NSCLC-N6 cell line after treatment, which led us to employ the "differential display" strategy. This powerful method makes ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.